Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2823-2832

  Goodin, Douglas S ^a,p   Biermann, Louis D ^b   Bohlega, Saeed ^c   Boiko, Alexey ^d   Chofflon, Michel ^e   Gebeily, Souheil ^f   Gouider, Riadh ^g   Havrdova, Eva ^h   Jakab, Gabor ⁱ   Karabudak, Rana ^j   Karussis, Dimitrios ^k   Miller, Ariel ^l   Pakdaman, Hossein ^m   Selmaj, Krzysztof ⁿ   Sharief, Mohammad ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b King Faisal Specialist Hospital and Research Centre ^*  (South Africa)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f Neuroscience Department   (Canada)

^g RAZI HOSPITAL   (Tunisia)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ Oncoradiology Center of Uzsoki Street Hospital   (Hungary)

^j HACETTEPE UNIVERSITY   (Turkey)

^k HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^l CARMEL MEDICAL CENTER   (Israel)

^m SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

^o GUY S HOSPITAL   (United Kingdom)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Evidence based medicine; Glatiramer acetate; Interferon beta; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LONG TERM CARE; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; HUMANS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 36348977483     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007X233007     Document Type: Review

References (35)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
2. Paty D, Li D, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a controlled multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial [The Copolymer 1 Multiple Sclerosis Study Group]. Neurology 1995;45:1268-76
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94
5. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
6. Li D, Paty D, UBC MS/MRI Analysis Research Group, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206
7. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25
8. Polman C, O'Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006;354:899-910
9. Sackett DL. Evidence based medicine: how to practice and teach EBM, 2nd ed. Edinburgh: Churchill Livingstone; 2000. p. 113-8
10. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 1998;11:618-29
11. Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol 2006;59:217-23
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-7
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
14. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
15. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999;18:53-63
16. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7
17. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon-beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
18. Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. I: analysis of clinical trial errors. J Neurol 2004;251(Suppl 5):v3-11
19. Biogen Inc. summary basis of approval. FDA official document for license of interferon beta-1a (Avonex), Cambridge (MA), 1995 [online]. Available at http://www.fda.gov/cder/biologics/sba/ifnbbio051796s.pdf
20. Goodin DS, Frohman EM, Garmany GP, Jr et al. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78
21. Durelli L, Verdun E, Barbero P, et al. E very-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
22. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-506
23. Panitch H, Goodin D, Francis G, et al. Benefit of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
24. Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004;251(Suppl 5):v42
25. Comi G, Filippi M, Wolinski JS. European/Canadian multicenter, double-blind randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7
26. Ford C, Johnson KP, Brooks B, et al. Sustained efficacy and tolerability of Copaxone (glatiramer acetate) in relapsing-remitting multiple sclerosis patients treated for over 10 years. Mult Scler 2003;9:P485
27. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006;354:911-23
28. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukloencephalopathy. New Engl J Med 2006;354:924-33
29. Francis GS. Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis. Expert Opin Drug Saf 2004;3:289-303
30. Paty DW, Kappos L, Stam Moraga M, et al.; for the PRISMS Study Investigators. Long-term observational efficacy and safety follow-up of the PRISMS cohort. Mult Scler 2003;9:S138
31. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
32. Ebers GC, Paty DW. Natural history studies and applications to clinical trials. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F.A. Davis Company; 1997. p. 192-228
33. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year followup study. Neurology 2004;62:51-9
34. Rice G, et al. European Committee for Treatment and Research in Multiple Sclerosis. Mult Scler 2001;7(Suppl 1):S1-137
35. Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-8